-
Loading metrics
Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the Alpha (B.1.1.7), Beta (B.1.351) and Delta variant (B.1.617.2)
- Anne Weiss ,
-
Franck Touret ,
Contributed equally to this work with: Anne Weiss, Franck Touret
Roles Conceptualization, Formal analysis, Methodology, Supervision, Writing – review & editing
Affiliation Unité des Virus Émergents (UVE: Aix-Marseille University -IRD 190-Inserm 1207-IHU Méditerranée, Infection), Marseille, France
⨯ - Cecile Baronti,
- Magali Gilles,
- Bruno Hoen,
- Antoine Nougairède,
- Xavier de Lamballerie ,
-
Morten O. A. Sommer
Roles Conceptualization, Funding acquisition, Supervision, Writing – original draft, Writing – review & editing
* E-mail: xavier.de-lamballerie@univ-amu.fr (XL); morten.sommer@uniontherapeutics.com, msom@biosustain.dtu.dk (MOAS)
¶‡ XL and MOAS are shared last authorship and treated as corresponding authors.
Affiliations Novo Nordisk Center for Biosustainability, Technical University Denmark, Lyngby, Denmark, UNION Therapeutics, Hellerup, Denmark
⨯
https://orcid.org/0000-0002-4734-2249
Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the Alpha (B.1.1.7), Beta (B.1.351) and Delta variant (B.1.617.2)
- Anne Weiss,
- Franck Touret,
- Cecile Baronti,
- Magali Gilles,
- Bruno Hoen,
- Antoine Nougairède,
- Xavier de Lamballerie,
- Morten O. A. Sommer
- Published: December 2, 2021
- https://doi.org/10.1371/journal.pone.0260958
- See the preprint